Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450.

Adverse drug event (ADE) rates resulting from coadministration of proton pump inhibitors (PPIs) and other drugs with potential for interaction with PPIs (DPIs) are unknown. This retrospective study assesses the occurrence of such ADEs and their potential impact on medical care costs by reviewing integrated medical and pharmacy claims. Managed care patients receiving one or more DPIs were identified.

Point-of-care versus laboratory monitoring of patients receiving different anticoagulant therapies.

Study Objective: To compare point-of-care and standard hospital laboratory assays for monitoring patients receiving single or combination anticoagulant regimens.

Design: Prospective analysis.

Setting: Nursing units and clinics at a large, community hospital.